Optimal dosing and side-effects

Injection Treatments in Cosmetic Surgery

Volumn , Issue , 2008, Pages 115-124

  Ascher, Benjamin ^a   Rossi, Bernard ^b  

^a Clinique Iena   (France)

^b Clinique Mathilde   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053032295     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (74)

1. Lamana C. The most poisonous poison. Science 1959; 130: 763-72.
2. Carruthers A, Kiene K, Carruthers J. Botulinum A exotoxin use in clinical dermatology. J Am Acad Dermatol 1996; 34: 788-97.
3. Matarasso SL. Complications of botulinum A exotoxin for hyperfunctional lines. Dermatol Surg 1998; 24: 1249-54.
4. Odergren T, Hjaltason H, Kaakkola S et al. A double blind, randomized, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998; 64: 6-12.
5. Ranoux D, Gury C, Fondarai J et al. Respective potencies of Botox and Dysport: a double blind randomized crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002; 72: 459-62.
6. Jost WH, Kohl A, Brinkmann S et al. Efficacy and tolerabil-ity of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J Neural Transm 2005; 112: 905-13.
7. Benecke R, Jost WH, Kanovsky P et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005; 64: 1949-51.
8. Roggenkämper P, Jost WH, Bihari K et al. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006; 113: 303-12.
9. Le Louarn C, Buthiau D, Buis J. Facial rejuvenation and concentric malar lift: the FACE RECURVE concept. Ann Chir Plast 2006; 51: 99-121.
10. Carruthers A, Lowe NJ, Menter MA et al. A multicenter, double-blind, randomised, placebo-controlled study of efficacy and safety of botulinum toxin type A in treatment of glabellar lines. J Am Acad Dermatol 2002; 46: 840-9.
11. Ascher B, Zakine B, Kestemont P et al. A multicenter, randomized, double blind, placebo-controlled study of botu-linum toxin A in treatment of glabellar lines. J Am Acad Dermatol 2004; 512: 223-33.
12. Klein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg 2003; 29: 549-56.
13. Ascher B, Zakine B, Kestemont P et al. A phase III, multicentre, randomized, double-blind, placebo-controlled study of efficacy and safety of 2 injections with 50 Speywood units of Botulinum Toxin A IPSEN in the treatment of glabellar frown lines. Cosmetic Botulinum Toxin Master Class. Paris: IMCAS, June 2004.
14. Sommer B, Sattler G. Cosmetic indications according to anatomic region. In: Botulinum Toxin in Aesthetic Medicine. Berlin: Blackwell Science, 2001, 30-55.
15. Benedetto AV. The cosmetic uses of botulinum toxin type A. Int J Dermatol 1999; 38: 641-55.
16. Sadick NS. Overview of complications of non surgical facial rejuvenation procedures. Clin Plast Surg 2001; 1: 163-76.
17. Ascher B, Klap P, Marion MH, Chanteloub B. La toxine bot-ulique dans le traitement des rides frontoglabellaires et de la région orbitaire. Ann Chir Plast Esthet 1995; 40: 67-76.
18. Binder WJ, Blitzer A, Brin MF. Treatment of hyperfunctional lines of the face with botulinum toxin A. Dermatol Surg 1998; 24: 1198-205.
19. Klein AW. Dilution and storage of botulinum toxin. Dermatol Surg 1998; 24: 1179-80.
20. Kim EJ, Ramirez AL, Reeck JB, Maas CS. The role of botu-linum toxin type B (Myobloc) in treatment of hyperkinetic lines. Plast Reconst Surg 2003; 112 (Suppl): 88S-93S.
21. Gury C. Aspects pharmacologiques du traitement par la toxine botulique. Réalités thérapeutiques en derm venero. 2004; 137: 7-12.
22. Ascher B. Toxine botulique, indications esthétiques, dermatologiques et réparatrices. In: Nieoullon A, Poulain B, Rascol O, Christen Y, eds. Les Amis du Clostridium, Tome 3, Toxine, Plasticité et Spasticité. Marseille: Solal, 2000: 11-18.
23. Markey AC. Botulinum A exotoxin in cosmetic dermatology. Clin Exp Dermatol 2000; 25: 173-5.
24. Carruthers A, Carruthers J. Treatment of glabellar frown lines with botulinum A exotoxin. J Dermatol Surg Oncol 1992; 18: 17-21.
25. Nicolau PJ, Chaouat M, Mimoun M. Skin, wrinkles and bot-ulinum toxin. Ann Readapt Med Phys 2003; 46: 361-74.
26. Prado AC, Andrales PR. Caution in using Botox in patients with previous facial surgery. Plast Reconstr Surg 2002; 109: 1472-3.
27. Sposito MM. New indications for botulinum toxin type A in cosmetics: mouth and neck. Plast Reconstr Surg 2002; 110: 601-11; discussion 612-13.
28. Matarasso SL, Matarasso A. Treatment guidlines for botu-linum toxin type A for the periocular region and a report of partial lip ptosis injections of the lateral canthus rhitids. Plast Reconstr Surg 2001; 108: 208-14; discussion 215-17.
29. Carruthers JD, Lowe NJ, Menter MA et al. Double-blind, placebo-controlled study of the efficacy and safety of botu-linum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003; 112: 1089-98.
30. Lowe NJ, Ascher B, Heckmann M et al. Botulinum toxin type A (Botox) in subjects with crow's feet, multicenter study. Dermatol Surg 2005; 31: 257-62.
31. Ascher B, Rzany B; Smile Study Groupe. Botulinum toxin type A (Dysport) in subjects with crow's feet, multicenter study, a single bilateral treatment of 15, 30, 45 u. Poster presented at EADV, Rhodes, Greece, October 2006.
32. Hexsel D, Mazzuco R, Zechmeister M, Hexsel CL. Complications and adverse effects: diagnosis and treatment. In: Hexsel D, Trindade de Almeida A, eds. Cosmetic Use of Botulinum Toxin. Porto Alegre: AGE Editora, 2002, 233-39.
33. Bullstrode NW, Grobelaar AO. Long-term prospective follow-up of botulinum toxin treatment for facial rhytides. Aesthetic Plast Surg 2002; 26: 356-9.
34. Alam M, Dover JS, Klein AW. Botulinum A exotoxin for hyper-functional facial lines. Dermatol Surg 2002; 138: 1180-5.
35. Le Louarn C. Botulinum toxin A and facial lines: the variable concentration. Aesthetic Plast Surg 2001; 25: 73-84.
36. Belhaouari L, Gassia V, Lauwers F. Frontalis muscular balance and botulinum toxin. Ann Chir Plast Esthet 2004; 49: 514-20.
37. Keen M, Blitzer A, Aviv J et al. Botulinum toxin A for hyperkinetic facial lines. Result of a double-blind, placebo-controlled study. Plast Reconstr Surg 1994; 103: 656-63.
38. Lowe NJ. Botulinum toxin A for facial rejuvenation. United States and United Kingdom perspectives. Dermatol Surg 1998; 24: 1216-18.
39. Wieder JM, Moy RL. Understanding botulinum toxin. Dermatol Surg 1998; 24: 1172-4.
40. Carruthers A, Carruthers JDA. Cosmetic uses of botulinum A exotoxin. Adv Dermatol 1997; 12: 325-48.
41. Manaloto RMP, Alster TS. Periorbital rejuvenation: a review of dermatologic treatments. Dermatol Surg 1999; 25: 1-8.
42. Garcia A, Fulton JE. Cosmetic denervation of muscles of facial expression with botulinum toxin A dose reponse study. Dermatol Surg 1996; 22: 39-43.
43. Carruthers A, Carruthers JDA. The adjunctive usage of botulinum toxin. Dermatol Surg 1998; 24: 1244-7.
44. Carruthers JDA, Carruthers A. A prospective, randomized, parallel group study analysing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane®) in combination compared with NASHA (Restylane®) alone in severe glabellar rhytides in adult female subjects. Dermatol Surg 2003; 29: 802-9.
45. Edelstein C, Shorr N, Jacobs J, Balch K, Goldberg R. Oculoplastic experience with the cosmetic use of botulinum A exotoxin. Dermatol Surg 1998; 24: 1208-12.
46. Sarrabayrouse MAM. Indications and limitations for the use of botulinum toxin for the treatment of facial wrinkles. Aesthetic Plast Surg 2002; 26: 233-8.
47. Carruthers JDA, Carruthers A. Botox® use in the mid and lower face and neck. Semin Cutan Med Surg 2001; 20: 85-92.
48. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991; 324: 1186-93.
49. Brant FS, Bellman B. Botulinum A exotoxin for platysmal bands and rejuvenation of the ageing neck. Dermatol Surg 1998; 24: 1232-4.
50. Matarasso A, Matarassso SL, Brant FS, Bellman B. Botulinum A exotoxin for the management of the platysma bands. Plast Reconstr Surg 1999; 103: 645-52.
51. Kane MAC. Non surgical treatment of platysma bands with injection of botulinum toxin A. Plast Reconstr Surg 1999; 103: 656-63.
52. Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 1994; 9: 31-9.
53. Harris CP, Alderson K, Nebeker J, Holds JB, Anderson RL. Histological features of human orbicularis oculi treated with botulinum A toxin. Arch Ophthalmol 1991; 109: 393-5.
54. Borodic GE, Gozzolino D. Pharmacology and Histology of Therapeutic Application of Botulinum Toxin. New York: Marcel Dekker, 1994.
55. Le Louarn C. The plastic surgeon and the prevention of facial aging process. Ann Chir Plast Esthet 2003; 48: 346-9.
56. Klein AW, Mantell A. Electromyographic guidance in injecting botulinum toxin. Dermatol Surg 1998; 24: 1184-6.
57. Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 1996; 46: 26-9.
58. Kessler KR, Skutta M, Benecke R. Long term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurol 1999; 246: 265-7.
59. Monheit G, Carruthers A, Brandt F et al. Double-blind, placebo-controlled study of efficacy and safety of botulinum toxin type A for patients with glabellar lines: determination of optimal dose. Dermatol Surg 2007; 33: 51-9.
60. FDA Medical Reviewer, 2002.
61. Carruthers A, Carruthers JDA. Cosmetic uses of botulinum A exotoxin. In: Klein AW, ed. Tissue Augmentation in Clinical Practice: Procedure and Techniques. New York: Marcel Dekker, 1998: 207-36.
62. National Institutes of Health. Clinical Use of Botulinum Toxin. NIH Consens Statement 1990; 8(8): 1-20.
63. Pickett A. Potency of type A botulinum toxin preparations in clinical use. Presented at 40th Annual Meeting of the Interagency Botulism Research Coordinating Committee (IBRCC), Atlanta, GA, 5-7 November, 2000.
64. Tugnoli Y, Eleopra R, Quartrale R et al. Botulism-like syndrome after BTX-A for local hyperhydrosis. Br J Dermatol 2002; 147: 808-9.
65. Bowden JB, Rapini RP. Psoriasiform eruption from intramuscular botulinum A toxin. Cutis 1992; 50: 415-16.
66. Cox NH, Duffey P, Royle J. Fixed drug eruption caused by lactose in an injected botulinum toxin preparation. J Am Acad Dermatol 1999; 40: 263-4.
67. Delgado MR. The use of botulinum toxin A in children with cerebral palsy: a retrospective study. Eur J Neurol 1999; 6 (Suppl 4): S11-18.
68. Boyd RN, Graham JEA, Natrass GR, Graham HK. Medium term response characterization and risk factor analysis of bot-ulinum toxin type A in management of spasticity in children with cerebral palsy. Eur J Neurol 1999; 6 (Suppl 4): S37-45.
69. Smuts JA, Baker MK, Smuts HM et al. Prophylactic treatment of chronic tension-type headache using botulinum toxin type A. Eur J Neurol 1999; 6 (Suppl 4): S99-102.
70. Racette BA, Lopate G, Good L, Sagitto S, Perlmutter JS. Ptosis as a remote effect of therapeutic botulinum toxin B injection. Neurology 2002; 59: 1445-7.
71. Lange DI, Brin MF, Warner C et al. Distant effects of locally injected botulinum toxin. Muscle Nerve 1987; 10: 552-5.
72. Park MY, Ahn KY. Botulinum toxin A for the treatment of hyperkinetic wrinkle lines. Plast Reconstr Surg 2003; 112 (Suppl): 148S-50S.
73. Ahn J, Horn C, Blitzer A. Botulinum toxin for masseter reduction in Asian patients. Arch Facial Plast Surg 2004; 6: 188-91.
74. Wang Y et al. Preparation of type A crystalline botulinum toxin for therapeutic and establishment of an experimental animal model. J Biol Prod 1990; 3: 121-5.